Calidi Biotherapeutics Inc Dossier
Qualitative Analysis
Business overview
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of targeted genetic medicines through its proprietary stem cell-based oncolytic virotherapy platforms. The company's technology is designed to shield oncolytic viruses from the patient's immune system, allowing them to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic payloads directly to metastatic locations. Calidi's pipeline features its systemically delivered RedTail platform, with lead candidate CLD-401 engineered to express a high-level IL-15 superagonist (IL-15 SA) to activate T and NK-cells in the tumor microenvironment. Other candidates include CLD-101 (NeuroNova) for high-grade gliomas and CLD-201 (SuperNova) for solid tumors and soft tissue sarcoma.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the capabilities of the RedTail platform to incorporate in situ T-cell engagers (TCEs) and bispecific T-cell engagers (BiTEs) targeting solid tumors (such as TROP-2), aiming to overcome traditional limitations of TCEs in solid tumors.
Expected impact: Differentiates Calidi's pipeline in the competitive immuno-oncology space and broadens the therapeutic utility of its systemic delivery platform.
Partnering with an international contract research organization to leverage Australia's streamlined clinical trial environment for rapid initiation of first-in-human trials.
Expected impact: Enables faster patient enrollment, regulatory efficiency, and early clinical validation of CLD-401.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Avance Clinical serves as the CRO to facilitate Australian regulatory approval and accelerate the initiation of the first-in-human Phase I clinical trial for CLD-401.
Terms: Not publicly disclosed
Matica Bio provides analytical development, process development, and GMP manufacturing of CLD-401 at its Texas facility to support the upcoming IND submission and clinical trials.
Terms: Not publicly disclosed
Utilizes TransferAI's proprietary agentic AI platform, Sofie, to drive efficiencies and streamline complex regulatory workflows in the IND submission process for CLD-401.
Terms: Not publicly disclosed